Expect this: modest, gradual improvements in appetite control and post-meal glucose handling over weeks to months
Common and Serious Side Effects The most frequent issues include nausea, vomiting, constipation, and diarrhea
6 Since then, states have altered their positions on covering anti-obesity GLP-1 therapies: Four have withdrawn coverage entirely (California, New Hampshire, Pennsylvania, and South Carolina), three have added coverage (Missouri, Tennessee, and Utah), and at least two states (Michigan and Virginia) have enacted more narrow utilization criteria, limiting future use to those with morbid obesity
The abdomen typically retains adequate subcutaneous tissue longest, but the thighs and arms may require technique adjustments as you progress
The choice between vendors often comes down to specific research needs